Why ED Drugs Stop Working
The medication did not fail. The supply it was amplifying ran out. Here is what is actually happening, and what addresses it at the source.
Last updated: April 5, 2026
The medication did not fail. The supply it was amplifying ran out. Here is what is actually happening, and what addresses it at the source.
Last updated: April 5, 2026
It worked for years, and then at some point it started requiring a higher dose, and then even that stopped being reliable. Most men assume this means the medication has lost its potency, or that their body has built up a tolerance to it over time. Both of those explanations point in the wrong direction, though, because the drug is actually behaving exactly as it's designed to. What's changed is something upstream of the drug entirely.
To understand why these medications eventually fail, it helps to understand what they're actually doing in the first place. Erections depend on blood flow, and blood flow into the penis requires the smooth muscle in the arterial walls to relax. That relaxation is triggered by a molecule called cyclic GMP, which the body produces in response to nitric oxide.
PDE5 inhibitors like Viagra (sildenafil) and Cialis (tadalafil) work by blocking an enzyme called phosphodiesterase type 5, which is the enzyme that normally breaks down cyclic GMP. By slowing that breakdown, the drugs extend how long whatever nitric oxide you've already produced can keep those arterial walls dilated and blood flowing in.
Think of it as slowing the drain in a filling bathtub. If the faucet is running well, slowing the drain maintains the water level just fine. But if the faucet has mostly stopped running, slowing the drain won't fill the tub no matter how much you adjust it. The drug's mechanism is intact. What's changed is how much nitric oxide the body's producing upstream of it, and that's the problem these medications were never designed to address.
Nitric oxide is produced by the endothelium, a thin layer of cells lining the inside of every blood vessel in the body. The enzyme responsible for making it, called eNOS, sits inside those cells and requires specific inputs and conditions to function properly. When those conditions deteriorate, so does the output.
As blood vessels age, particularly under conditions like elevated blood sugar, high blood pressure, or chronic inflammation, endothelial function gradually declines. The cells produce less nitric oxide as a result, which means the signal the PDE5 inhibitor was amplifying gets progressively weaker over time.
There's also a specific compound that accelerates this decline. ADMA, short for asymmetric dimethylarginine, is a naturally occurring molecule that directly blocks eNOS, and it tends to accumulate when insulin resistance is present, when kidney function is impaired, or when oxidative stress is elevated. A 2012 study by Paroni et al. found that men with arteriogenic erectile dysfunction had significantly higher ADMA concentrations than healthy controls, suggesting that their endothelium wasn't producing less nitric oxide simply because of age, but because ADMA was blocking the enzyme responsible for making it.
When the supply of nitric oxide falls below a functional threshold, there's simply not enough signal for the medication to amplify, and reaching for a higher dose won't change the underlying reason that's happening.
PDE5 inhibitors are downstream interventions, which means they work on what happens after nitric oxide is produced, but they can't do anything to restore the capacity to produce it. That distinction becomes more significant the longer endothelial damage has been accumulating, because the gap between what the body can produce and what it needs to produce keeps widening.
The anatomical context here is worth sitting with for a moment. The arteries supplying the penis measure about 1 to 2 millimeters in diameter, while the coronary arteries supplying the heart measure 3 to 4 millimeters. Because endothelial dysfunction affects smaller vessels first, sexual function typically declines well before any cardiac symptoms appear, which is why ED is increasingly understood as an early vascular signal rather than just a sexual health issue.
Research by Montorsi et al. found that in men who went on to develop documented coronary artery disease, erectile dysfunction had preceded their cardiac event by an average of 39 months. Of men presenting with confirmed coronary artery disease, 49% reported prior onset of ED. That's not a coincidence of aging. Both conditions are driven by the same underlying process, endothelial dysfunction working its way through vessels of progressively larger diameter.
So when someone stops responding to a PDE5 inhibitor, it's worth taking seriously not just as a sexual health problem, but as a potential early indicator of broader vascular decline.
Addressing endothelial function means working on the upstream supply, the faucet rather than the drain. The interventions that have the most clinical support are dietary and metabolic, and they're not fast, since most operate on a 60 to 90 day timeline before measurable change becomes visible.
Dietary nitrates. Green leafy vegetables, particularly arugula, spinach, and beets, provide dietary nitrates that the body converts to nitric oxide through a bacteria-dependent pathway in the mouth and gut. That pathway actually bypasses eNOS entirely, so it remains functional even when the endothelium is significantly compromised. It's not a replacement for restored endothelial function, but it's a meaningful input that's available while the longer repair process is underway.
L-citrulline. L-citrulline is a precursor to arginine, the amino acid that eNOS uses as its raw material to produce nitric oxide. It's more bioavailable than taking L-arginine directly, because it bypasses the first-pass metabolism that happens in the gut and liver and leaves more available in the bloodstream. A 2011 randomized controlled trial by Cormio et al., published in Urology, found that men taking 1.5 grams per day for one month showed significant improvements in erection hardness scores compared to placebo, which is a meaningful result given that it's working on the upstream problem PDE5 inhibitors can't reach.
Blood sugar control. Elevated glucose directly damages endothelial cells and, as mentioned earlier, accelerates ADMA accumulation. The FAMe 2.0 study, which examined men with type 2 diabetes and ED, found that glycemic control was independently associated with improvements in erectile function scores. For men whose ED has a metabolic component, managing fasting glucose and the blood sugar spikes that follow meals tends to be one of the highest-leverage changes available.
Blood pressure. Sustained hypertension damages the endothelium mechanically through chronic shear stress. Bringing blood pressure down, particularly through lifestyle modification rather than medication alone, reduces that mechanical load and creates the conditions the endothelium needs to recover over time.
What's worth knowing about all of these is that results don't announce themselves in the first few weeks. The 90-day re-test is the point where measurable change becomes visible, and without a before and after measurement, it's easy to walk away from a protocol that was actually working because there was no way to see that it was.
Most annual physicals don't measure vascular age. They measure cholesterol and blood pressure, both of which are useful, but neither one tells you how fast your arteries are aging relative to the rest of your body. That gap is where a lot of men find themselves, knowing something is declining but not having a number attached to it.
GRN Labs built a free vascular age calculator that estimates where your vascular system likely sits, based on 15 questions covering blood pressure history, metabolic markers, lifestyle inputs, and symptoms. It takes a few minutes. What you get is a starting reference point, which is the one thing you need before any protocol makes sense, because without a baseline there's no way to tell whether what you're doing is actually working.
At 90 days into a vascular protocol, you re-test the same markers. The gap between the first number and the second is the closest thing to an honest answer about whether what you're doing is actually changing anything.
PDE5 inhibitors extend the duration of whatever nitric oxide the body has already produced, but the drugs themselves don't generate any of it. So as endothelial function declines and the upstream supply of nitric oxide falls, there's progressively less signal for the medication to work with. Once the supply drops below a functional threshold, even a higher dose won't change the outcome.
It's worth treating it as one. Research by Montorsi et al. found that in men who went on to develop documented coronary artery disease, ED had preceded their cardiac event by an average of 39 months. Because the arteries supplying the penis are smaller than the coronary arteries, they show endothelial damage first, which is why sexual function often declines years before any cardiac symptoms appear. A loss of drug response is worth investigating upstream, rather than managing with a higher dose.
L-citrulline provides the substrate that eNOS uses to produce nitric oxide, so it's working on the supply side rather than the amplification side. A 2011 randomized trial by Cormio et al. found significant improvement in erection hardness scores at 1.5g per day over one month, which is a meaningful result given that it's addressing the upstream problem that PDE5 inhibitors weren't designed to reach.
Vascular adaptation doesn't happen quickly, and that's one of the main reasons people abandon protocols that are actually working. The standard timeline is 60 to 90 days before measurable change becomes visible. During that period, the endothelium is responding to the inputs, but the results aren't yet quantifiable, which is why having a baseline number to compare against at 90 days makes such a practical difference.
GRN Labs provides educational content and data-driven biomarker audits. We are not medical doctors, and nothing on this website constitutes medical advice, diagnosis, or treatment. This content is for informational purposes only and is not intended to replace the relationship between you and a qualified healthcare provider.
These statements have not been evaluated by the Food and Drug Administration (FDA). Any products or protocols discussed are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Always consult your physician before beginning any new supplement, diet, or health regimen.
See what your doctor missed
Answer 15 questions. Get your estimated vascular age score in minutes.
Get My Vascular Age Score